tetano
Editor, Senior Moderator
IJTLD Open
. 2024 Oct 1;1(10):443-448.
doi: 10.5588/ijtldopen.24.0180. eCollection 2024 Oct. Predictors of interferon-gamma release assay results and their association with COVID-19 infection outcomes
S J W Kang[SUP] 1 2 3 [/SUP], G W Eather[SUP] 1 2 3 [/SUP], F Qureshi[SUP] 1 [/SUP], J R Scott[SUP] 4 [/SUP]
Affiliations
in English, French
Background: An 'indeterminate' interferon-gamma release assay (IGRA) result used in the diagnosis of latent TB infection (LTBI) is most commonly due to an inadequate control (or 'mitogen') response, which may reflect underlying T-cell dysfunction.
Methods: We performed a single-centre, retrospective study on COVID-19 patients admitted to a tertiary referral hospital who had IGRA testing conducted over a 5-month period. The primary outcomes included predictors of indeterminate IGRA results and associations with COVID-19 outcomes.
Results: A total of 181 patients were included for analysis. Approximately one-third of patients hospitalised with COVID-19 with IGRA testing performed (60/181) had an indeterminate result. The likelihood of an indeterminate IGRA was increased in patients with a history of solid organ transplant and a higher severity of COVID-19 at the time of testing. An indeterminate IGRA was associated with a higher risk of severe COVID-19 and a higher risk of admission to the ICU during admission to the hospital. No difference in mortality between the two subgroups was found.
Conclusion: Our study demonstrated that COVID-19 patients on immunosuppression had a high likelihood of an indeterminate IGRA result, which was associated with markers of disease severity and immunosuppression. In this cohort, an indeterminate result was associated with worse COVID-19 outcomes.
Keywords: Coronavirus disease 2019; IGRA; immunosuppression.
. 2024 Oct 1;1(10):443-448.
doi: 10.5588/ijtldopen.24.0180. eCollection 2024 Oct. Predictors of interferon-gamma release assay results and their association with COVID-19 infection outcomes
S J W Kang[SUP] 1 2 3 [/SUP], G W Eather[SUP] 1 2 3 [/SUP], F Qureshi[SUP] 1 [/SUP], J R Scott[SUP] 4 [/SUP]
Affiliations
- PMID: 39398431
- PMCID: PMC11467851
- DOI: 10.5588/ijtldopen.24.0180
in English, French
Background: An 'indeterminate' interferon-gamma release assay (IGRA) result used in the diagnosis of latent TB infection (LTBI) is most commonly due to an inadequate control (or 'mitogen') response, which may reflect underlying T-cell dysfunction.
Methods: We performed a single-centre, retrospective study on COVID-19 patients admitted to a tertiary referral hospital who had IGRA testing conducted over a 5-month period. The primary outcomes included predictors of indeterminate IGRA results and associations with COVID-19 outcomes.
Results: A total of 181 patients were included for analysis. Approximately one-third of patients hospitalised with COVID-19 with IGRA testing performed (60/181) had an indeterminate result. The likelihood of an indeterminate IGRA was increased in patients with a history of solid organ transplant and a higher severity of COVID-19 at the time of testing. An indeterminate IGRA was associated with a higher risk of severe COVID-19 and a higher risk of admission to the ICU during admission to the hospital. No difference in mortality between the two subgroups was found.
Conclusion: Our study demonstrated that COVID-19 patients on immunosuppression had a high likelihood of an indeterminate IGRA result, which was associated with markers of disease severity and immunosuppression. In this cohort, an indeterminate result was associated with worse COVID-19 outcomes.
Keywords: Coronavirus disease 2019; IGRA; immunosuppression.